Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.70035 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Marie B Weitemeyer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was supported by the SkylineDx..
Abstract (Originalsprache)
Background
Sentinel lymph node biopsy (SLNB) is crucial for staging and managing melanoma, but selecting patients for SLNB is challenging, with around 80% of procedures yielding negative results. The clinicopathological and gene expression profile model (CP‐GEP) was developed to identify low‐risk melanoma patients who may forgo SLNB. CP‐GEP combines Breslow thickness, patient age, and a gene expression analysis to classify patients as high‐ or low‐risk for nodal metastasis. This study aimed to validate the performance of CP‐GEP in a multicenter Danish cohort.
Method
Primary melanoma tissue from 536 T1‐T3 patients who had undergone SLNB was retrospectively analyzed using CP‐GEP. Results were compared with SLNB status and the Melanoma Institute Australia nomogram (MIA).
Results
T1, T2, and T3 melanomas comprised 32.8%, 46.8%, and 20.3% of cases, respectively. The SLNB positivity rate was 18.1%. Overall, 40.9% was classified as CP‐GEP low‐risk (NPV 91.3%). Among T1 and T2 subgroups, 72.7% and 35.5% were low‐risk, with NPVs of 94.5% and 87.6%, respectively. For 507 patients with MIA scores, CP‐GEP identified 42.4% as low‐risk (NPV 91.2%) versus 8.1% by MIA (NPV 95.1%).
Conclusion
CP‐GEP is a promising tool for supporting deselection of SLNB in melanoma patients, with a potential reduction rate of over 40%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- AGATA Private Hospital, Copenhagen, Denmark.
Förderung
- This research was supported by the SkylineDx.
Zitieren
APA
Weitemeyer, M. B., Helvind, N. M., Klausen, S., Clasen-Linde, E., Schmidt, G., Chakera, A. H., & Hölmich, L. R. (2025). Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70035
Vancouver
Weitemeyer MB, Helvind NM, Klausen S, Clasen-Linde E, Schmidt G, Chakera AH, et al. Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study. Journal of Surgical Oncology. 2025. doi:10.1002/jso.70035
BibTeX
@article{Weitemeyer2025,
author = {Weitemeyer, Marie B and Helvind, Neel M and Klausen, Siri and Clasen-Linde, Erik and Schmidt, Grethe and Chakera, Annette H and Hölmich, Lisbet R},
title = {Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.70035}
}
EUVIMED